Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Nathan

Showing results (171-180 of 245) with videos related to

Pageof 25
Sort By:
Archives of Ophthalmology (Chicago, Ill. : 1960)|December 10, 2008
Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications TrialNeil H White, Wanjie Sun, Patricia A Cleary, et al.
BMJ Open Diabetes Research & Care|May 30, 2024
Within and post-trial effects of an intensive lifestyle intervention on kidney disease in adults with overweight or obesity and type 2 diabetes mellitus: a secondary analysis of the Look AHEAD clinical trialWilliam C Knowler, Haiying Chen, Judy L Bahnson, et al.
The New England Journal of Medicine|July 21, 2006
TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention ProgramJose C Florez, Kathleen A Jablonski, Nick Bayley, et al.
Diabetes|March 29, 2005
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention ProgramWilliam C Knowler, Richard F Hamman, Sharon L Edelstein, et al.
Metabolism: Clinical and Experimental|October 23, 2009
The association of tumor necrosis factor alpha receptor 2 and tumor necrosis factor alpha with insulin resistance and the influence of adipose tissue biomarkers in humansMarie-France Hivert, Lisa M Sullivan, Peter Shrader, et al.
The Journal of Clinical Endocrinology and Metabolism|January 11, 2007
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazoneJose C Florez, Kathleen A Jablonski, Maria W Sun, et al.
Diabetologia|October 11, 2025
Shared and distinct metabolomics profiles associated with microvascular complications in the Diabetes Prevention Program Outcomes StudyWei Perng, Shiyu Shu, David M Nathan, et al.
The New England Journal of Medicine|June 17, 2014
Outpatient glycemic control with a bionic pancreas in type 1 diabetesSteven J Russell, Firas H El-Khatib, Manasi Sinha, et al.
Critical Pathways in Cardiology|December 3, 2009
An algorithm for the care of type 2 diabetesAlan Cole, David M Nathan, Elizabeth Savaria-Porter, et al.
Diabetes Care|April 12, 2014
Musculoskeletal complications in type 1 diabetesMary E Larkin, Annette Barnie, Barbara H Braffett, et al.
Pageof 25

Showing results (171-180 of 245) with videos related to

Sort By:
Pageof 25
Archives of Ophthalmology (Chicago, Ill. : 1960)|December 10, 2008
Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications TrialNeil H White, Wanjie Sun, Patricia A Cleary, et al.
BMJ Open Diabetes Research & Care|May 30, 2024
Within and post-trial effects of an intensive lifestyle intervention on kidney disease in adults with overweight or obesity and type 2 diabetes mellitus: a secondary analysis of the Look AHEAD clinical trialWilliam C Knowler, Haiying Chen, Judy L Bahnson, et al.
The New England Journal of Medicine|July 21, 2006
TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention ProgramJose C Florez, Kathleen A Jablonski, Nick Bayley, et al.
Diabetes|March 29, 2005
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention ProgramWilliam C Knowler, Richard F Hamman, Sharon L Edelstein, et al.
Metabolism: Clinical and Experimental|October 23, 2009
The association of tumor necrosis factor alpha receptor 2 and tumor necrosis factor alpha with insulin resistance and the influence of adipose tissue biomarkers in humansMarie-France Hivert, Lisa M Sullivan, Peter Shrader, et al.
The Journal of Clinical Endocrinology and Metabolism|January 11, 2007
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazoneJose C Florez, Kathleen A Jablonski, Maria W Sun, et al.
Diabetologia|October 11, 2025
Shared and distinct metabolomics profiles associated with microvascular complications in the Diabetes Prevention Program Outcomes StudyWei Perng, Shiyu Shu, David M Nathan, et al.
The New England Journal of Medicine|June 17, 2014
Outpatient glycemic control with a bionic pancreas in type 1 diabetesSteven J Russell, Firas H El-Khatib, Manasi Sinha, et al.
Critical Pathways in Cardiology|December 3, 2009
An algorithm for the care of type 2 diabetesAlan Cole, David M Nathan, Elizabeth Savaria-Porter, et al.
Diabetes Care|April 12, 2014
Musculoskeletal complications in type 1 diabetesMary E Larkin, Annette Barnie, Barbara H Braffett, et al.
Pageof 25